Zevra Therapeutics Inc.

06/05/2026 | Press release | Distributed by Public on 06/05/2026 14:19

Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders.
At the 2026 Annual Meeting of Stockholders of Zevra Therapeutics, Inc. (the "Company") held on June 4, 2026 (the "Annual Meeting"), the stockholders of the Company voted on the following matters, which are described in detail in the Company's Definitive Proxy Statement filed with the Securities and Exchange Commission on April 20, 2026 (File No. 001-36913) (the "Proxy Statement"): (1) to elect Douglas W. Calder and Corey Watton to the Company's Board as Class II directors to hold office until the 2029 annual meeting of stockholders, and until their respective successors shall have been duly elected and qualified ("Proposal 1"); (2) to ratify the appointment of Ernst and Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026 (Proposal 2); and (3) to approve an amendment to the Company's Restated Certificate of Incorporation (the "Charter") to phase out the classified Board structure and provide that all directors elected at or after the 2027 annual meeting of stockholders be elected on an annual basis (Proposal 3). Of the 59,114,850 shares of the Company's common stock outstanding and entitled to vote as of April 6, 2026 (the "Record Date"), 46,326,616 shares, or 78.37%, voted.
The tabulation of votes with respect to the proposals at the Annual Meeting was as follows:
Proposal 1 - Election of Directors:
For
Withheld
Broker Non-Votes
Douglas W. Calder
25,754,763
7,964,919
12,606,934
Corey Watton
29,878,306
3,841,376
12,606,934
Proposal 2 - Ratification of Ernst & Young LLP as the Company's Independent Registered Public Accounting Firm:
For
Against
Abstain
Broker Non-Votes
45,947,281
234,753
144,582
-
Proposal 3 - Vote to Approve an Amendment to the Charter to Declassify the Board:
For
Against
Abstain
Broker Non-Votes
32,557,653
1,145,079
16,950
12,606,934
Accordingly, stockholders have voted to elect the two director nominees on Proposal 1 and in favor of Proposal 2 to ratify the appointment of Ernst & Young. Proposal 3, which required the affirmative vote of more than 66 2/3% of the Company's outstanding common stock as of the Record Date, did not receive the required vote.
Zevra Therapeutics Inc. published this content on June 05, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on June 05, 2026 at 20:19 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]